Quick answer: state medical board peptide therapy oversight works through general rules, not peptide-specific laws. Boards judge any peptide or compounded GLP-1 prescription against the standard of care: a real patient relationship, an individualized exam, informed consent, good records, truthful advertising, and lawful compounding. The Federation of State Medical Boards (FSMB) set out 11 recommendations on these points in May 2026.[1] Prescribing an unapproved peptide such as BPC-157 also runs into federal drug law, which a state license does not override.
This guide covers who regulates what, what the boards have actually said, and what gets prescribers disciplined. For the federal side, see our FDA peptide ban 2026 explainer, the 503A vs 503B compounding guide, and the FDA & Regulation hub.
Who regulates peptide therapy
Four regulators share the territory, and the FSMB itself calls it a “regulatory gray zone”:[1]
| Regulator | What it controls |
|---|---|
| State medical boards | The practice of medicine: who may prescribe, the exam, records, advertising by licensees |
| State pharmacy boards | Pharmacies and compounding, including ingredient sourcing |
| FDA | Drugs, approval status, compounding ingredient lists, drug claims |
| FTC | Advertising, deceptive marketing, unfair business practices |
So a single clinic visit can raise questions for all four. A physician can lose a license over a peptide regimen even if no federal agency acts, and a federal warning letter does not by itself discipline a license.
What the FSMB’s 2026 guidance says
The FSMB is the national association of state boards. Its policies are models, not law, but boards often adopt them. In May 2026 its House of Delegates adopted Guidance on Recent Trends in Prescribing and Dispensing, which covers IV hydration clinics, ketamine, medical spas, and GLP-1 weight-loss clinics.[1] The points most relevant to peptides:
- Patient relationship. A valid practitioner-patient relationship is required whether care is in person or by telemedicine.
- No menu medicine. Prescribing “based solely on a patient-driven selection from a ‘menu’ of options does not meet the standard of care.” Static online questionnaires alone are “not acceptable.”
- Personal evaluation. The prescriber, or a properly delegated PA, must personally evaluate and diagnose the patient and decide the treatment will actually help.
- Compounding. Compounding must be patient-specific, medically necessary, and compliant with USP chapters 795, 797 and 800. Physicians are encouraged not to compound when an FDA-approved drug is available, and clinics that do not compound must buy from a licensed pharmacy or a registered 503B outsourcing facility.
- Advertising. Ads must not be deceptive, and claims should be backed by documented evidence such as peer-reviewed studies.
The telemedicine rules build on the FSMB’s April 2022 policy, which says the same standard of care applies whether care is delivered in person or virtually.[2] Our telehealth peptide prescriptions guide covers that side in more depth.
Off-label prescribing and the standard of care
“Off-label” means using an FDA-approved drug for a use not on its label. FDA’s position is that doctors “generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate.”[3] Prescribing semaglutide for a patient who does not fit the label is one example.
Two limits matter for peptides:
- Off-label applies only to approved drugs. BPC-157, TB-500 and most “wellness” peptides have no FDA approval for any use, so there is no label to go “off.” The question becomes whether a pharmacy may lawfully compound them, which is a federal compounding question.
- Off-label still has to meet the standard of care. Boards ask whether the prescriber had a reason grounded in evidence, explained the risks and alternatives, monitored the patient, and documented it.[1]
What state boards have said about compounded GLP-1s
GLP-1 drugs are peptides, and most board statements so far are about them.
- Alabama. In September 2023 the Board of Medical Examiners warned about predatory pharmacy practices, physicians compounding semaglutide in their offices, and “improper evaluation” without proper histories, physicals, testing or follow-up. It also flagged reports of out-of-state pharmacies soliciting doctors with per-prescription kickbacks.[4]
- Oregon. The Board of Pharmacy’s February 2025 statement says semaglutide may only be compounded from the base form, from pharmaceutical-grade ingredient with a certificate of analysis, from an FDA-registered establishment. “Research use only” material may not be used in any circumstance, and a lower price alone does not justify compounding.[5]
- Florida. The Board of Medicine has a standing rule on prescribing drugs to treat obesity. Its 2022 amendment updated the standards and allowed telemedicine prescribing for weight management.[6]
Federal context changed the ground under these statements. FDA declared the tirzepatide injection shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025, which narrowed when copies of those drugs can be compounded.[11][12] See compounded semaglutide vs Ozempic and the tirzepatide profile for details.
What gets prescribers disciplined
Public actions tend to involve conduct around the drug, not the peptide alone.
- Unsafe in-office compounding. In June 2026 the Medical Board of California filed an accusation seeking to revoke a San Diego physician’s license. It alleges he let a pharmacist make semaglutide and tirzepatide in his office without a certified cleanroom, with mislabeled products lacking expiration dates. These are allegations, not findings.[8]
- Prescribing without an indication or expertise. Outside the U.S., the Medical Board of Australia reported in 2019 that a tribunal suspended a general practitioner for four months for prescribing IGF-1 to six patients by phone, without a proper therapeutic indication and with a misleading consent waiver.[9]
The common threads match the FSMB list: no real evaluation, no records, poor sourcing, and misleading claims.[1]
Where non-GLP-1 peptides fit in 2026
For compounded peptides like BPC-157, Semax and epitalon, the federal status still sets the outer limit:
- FDA’s “significant safety risks” page, current as of April 22, 2026, lists BPC-157, Semax, TB-500, thymosin alpha-1 and others as nominations that were withdrawn. GHRP-2, GHRP-6, ipamorelin and kisspeptin-10 remain in Category 2.[7]
- Leaving Category 2 is not approval. None of these peptides is on the 503A bulks list.
- On October 15, 2026, HHS and FDA sent an “interim access policy” on compounding certain peptides to the White House for review. The AP reported it would let pharmacies temporarily compound some peptides, including BPC-157. No terms had been published as of October 18, 2026.[10]
A board will expect a prescriber to know where a product sits on these lists. For background, see BPC-157 legal status and the FDA peptide regulation timeline.
What patients can check
- License and discipline. Search your state medical board’s license lookup for public orders.
- The visit. A legitimate prescriber takes a history, reviews your medications, orders labs when needed, explains risks, and schedules follow-up.
- The product. Ask which pharmacy made it, and whether it is a 503A pharmacy or a 503B outsourcing facility. “Research use only” vials are not prescription drugs.
- The claims. Be wary of “FDA-approved” or “same as” claims for compounded products. See our guide to peptide advertising rules.
This is general information, not legal advice. Rules differ by state, and prescribers should check their own board’s current rules or consult a health care attorney.
